2023
Seasonal Malaria Chemoprevention Drug Levels and Drug Resistance Markers in Children With or Without Malaria in Burkina Faso: A Case-Control Study
Roh M, Zongo I, Haro A, Huang L, Somé A, Yerbanga R, Conrad M, Wallender E, Legac J, Aweeka F, Ouédraogo J, Rosenthal P. Seasonal Malaria Chemoprevention Drug Levels and Drug Resistance Markers in Children With or Without Malaria in Burkina Faso: A Case-Control Study. The Journal Of Infectious Diseases 2023, 228: 926-935. PMID: 37221018, PMCID: PMC10547452, DOI: 10.1093/infdis/jiad172.Peer-Reviewed Original ResearchConceptsSeasonal malaria chemopreventionDrug levelsMonths of ageOdds ratioHigh-level SP resistanceSP-AQCase-control studyConditional logistic regressionLow drug levelsPrevalence of mutationsDrug resistance markersCase-control designResistance markersIncident malariaParasitemic childrenMalaria chemopreventionAntimalarial resistanceChildren 6Health facilitiesSP resistanceChildren 3Malaria incidenceDrug resistanceMalariaLogistic regression
2022
Prevalence of Plasmodium falciparum haplotypes associated with resistance to sulfadoxine–pyrimethamine and amodiaquine before and after upscaling of seasonal malaria chemoprevention in seven African countries: a genomic surveillance study
Beshir K, Muwanguzi J, Nader J, Mansukhani R, Traore A, Gamougam K, Ceesay S, Bazie T, Kolie F, Lamine M, Cairns M, Snell P, Scott S, Diallo A, Merle C, NDiaye J, Razafindralambo L, Moroso D, Ouedraogo J, Zongo I, Kessely H, Doumagoum D, Bojang K, Ceesay S, Loua K, Maiga H, Dicko A, Sagara I, Laminou I, Ogboi S, Eloike T, Milligan P, Sutherland C. Prevalence of Plasmodium falciparum haplotypes associated with resistance to sulfadoxine–pyrimethamine and amodiaquine before and after upscaling of seasonal malaria chemoprevention in seven African countries: a genomic surveillance study. The Lancet Infectious Diseases 2022, 23: 361-370. PMID: 36328000, DOI: 10.1016/s1473-3099(22)00593-x.Peer-Reviewed Original ResearchConceptsSeasonal malaria chemopreventionMalaria chemopreventionResistance-associated variantsParasite carriageSurvey-weighted prevalenceMalaria transmission seasonQuantitative PCRPrevalence ratiosP falciparumGenomic surveillance studyChemoprevention drugsBlood samplesSurveillance studyTransmission seasonChemopreventionPlasmodium falciparumAmodiaquinePrevalenceMDR1Variant haplotypeSequencing of isolatesSignificant reductionChildrenPyrimethamineCommunity surveyEthical considerations in deploying triple artemisinin-based combination therapies for malaria: An analysis of stakeholders’ perspectives in Burkina Faso and Nigeria
Tindana P, Guissou R, Bolarinwa O, Tou F, de Haan F, Dhorda M, Dondorp A, Amaratunga C, Mokuolu O, Ouedraogo J, Cheah P. Ethical considerations in deploying triple artemisinin-based combination therapies for malaria: An analysis of stakeholders’ perspectives in Burkina Faso and Nigeria. PLOS ONE 2022, 17: e0273249. PMID: 36083995, PMCID: PMC9462557, DOI: 10.1371/journal.pone.0273249.Peer-Reviewed Original ResearchConceptsTriple artemisinin-based combination therapiesArtemisinin-based combination therapyCombination therapyArtemisinin resistanceUncomplicated Plasmodium falciparum malariaDrug resistancePlasmodium falciparum malariaMalaria-endemic countriesPartner drug resistanceAdditional side effectsUncomplicated malariaFalciparum malariaTreatment optionsEndemic countriesPediatric diseasesSide effectsACT failureMalariaTherapyBurkina FasoFocus group discussionsEthical considerationsTreatmentQualitative studyStakeholder engagement activities
2020
Effectiveness of seasonal malaria chemoprevention at scale in west and central Africa: an observational study
Partnership A, Baba E, Hamade P, Kivumbi H, Marasciulo M, Maxwell K, Moroso D, Roca-Feltrer A, Sanogo A, Johansson J, Tibenderana J, Abdoulaye R, Coulibaly P, Hubbard E, Jah H, Lama E, Razafindralambo L, Van Hulle S, Jagoe G, Tchouatieu A, Collins D, Gilmartin C, Tetteh G, Djibo Y, Ndiaye F, Kalleh M, Kandeh B, Audu B, Ntadom G, Kiba A, Savodogo Y, Boulotigam K, Sougoudi D, Guilavogui T, Keita M, Kone D, Jackou H, Ouba I, Ouedraogo E, Messan H, Jah F, Kaira M, Sano M, Traore M, Ngarnaye N, Elagbaje A, Halleux C, Merle C, Iessa N, Pal S, Sefiani H, Souleymani R, Laminou I, Doumagoum D, Kesseley H, Coldiron M, Grais R, Kana M, Ouedraogo J, Zongo I, Eloike T, Ogboi S, Achan J, Bojang K, Ceesay S, Dicko A, Djimde A, Sagara I, Diallo A, NdDiaye J, Loua K, Beshir K, Cairns M, Fernandez Y, Lal S, Mansukhani R, Muwanguzi J, Scott S, Snell P, Sutherland C, Tuta R, Milligan P. Effectiveness of seasonal malaria chemoprevention at scale in west and central Africa: an observational study. The Lancet 2020, 396: 1829-1840. PMID: 33278936, PMCID: PMC7718580, DOI: 10.1016/s0140-6736(20)32227-3.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAfrica, CentralAfrica, WesternAmodiaquineAntimalarialsCase-Control StudiesChemopreventionChildCost-Benefit AnalysisDrug CombinationsDrug ResistanceFeasibility StudiesHumansIncidenceMalariaProgram EvaluationPyrimethamineSafetySeasonsSulfadoxineSurveys and QuestionnairesYoung AdultConceptsSeasonal malaria chemopreventionCase-control studyHigh transmission periodMalaria chemopreventionObservational studyHealth-care staff timeHigh malaria transmission seasonDrug resistanceSerious adverse drug reactionsMalaria transmission seasonSerious adverse reactionsSevere skin reactionsCommunity health workersNational health management information systemAdverse drug reactionsCost-effectiveness ratioHealth Management Information SystemIndividual case safetyTarget populationMarker of resistanceSMC treatmentHospital admissionOutpatient clinicDrug reactionsSkin reactionsInvestigating selected host and parasite factors potentially impacting upon seasonal malaria chemoprevention in Bama, Burkina Faso
Somé FA, Bazié T, Ehrlich HY, Goodwin J, Lehane A, Neya C, Zachari K, Wade M, Ouattara JM, Foy BD, Dabiré RK, Parikh S, Ouédraogo JB. Investigating selected host and parasite factors potentially impacting upon seasonal malaria chemoprevention in Bama, Burkina Faso. Malaria Journal 2020, 19: 238. PMID: 32631416, PMCID: PMC7339464, DOI: 10.1186/s12936-020-03311-8.Peer-Reviewed Original ResearchConceptsSeasonal malaria chemopreventionDay 7 concentrationsSMC administrationMalaria chemopreventionMalaria infectionDay 7 plasma concentrationsHigh malaria transmission seasonBlood spotsFirst monthPfcrt 76TPrevalence of microscopicSubmicroscopic malaria infectionMalaria transmission seasonPlasmodium falciparum infectionPfcrt K76THigh transmission settingsSequential cross-sectional surveysCross-sectional surveyNon-significant trendAmodiaquine metabolismPfmdr1 N86Malaria parasitaemiaFalciparum infectionK76TPlasma concentrations
2016
Polymorphisms in K13, pfcrt, pfmdr1, pfdhfr, and pfdhps in parasites isolated from symptomatic malaria patients in Burkina Faso
Somé A, Sorgho H, Zongo I, Bazié T, Nikiéma F, Sawadogo A, Zongo M, Compaoré Y, Ouédraogo J. Polymorphisms in K13, pfcrt, pfmdr1, pfdhfr, and pfdhps in parasites isolated from symptomatic malaria patients in Burkina Faso. Parasite 2016, 23: 60. PMID: 28004634, PMCID: PMC5178381, DOI: 10.1051/parasite/2016069.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntigens, BacterialAntigens, SurfaceAntimalarialsArtemisininsBurkina FasoChildChild, PreschoolDrug ResistanceDrug Therapy, CombinationHumansInfantMalaria, FalciparumMembrane Transport ProteinsMultidrug Resistance-Associated ProteinsPlasmodium falciparumPolymorphism, Single NucleotideProtozoan ProteinsYoung AdultConceptsPolymerase chain reactionUncomplicated malariaDrug resistance polymorphismsPfcrt 76TResistance-mediating polymorphismsPrevalence of polymorphismsSymptomatic malaria patientsAntimalarial drug resistanceGlobal malaria controlEmergence of resistancePfmdr1 184FPfmdr1 86YMalaria patientsPfdhps genesBaseline prevalenceCombination therapyHealth centersBlood samplesWestern CambodiaBetter efficacyGene polymorphismsCodon 540Malaria controlDrug resistancePfdhpsA Worldwide Map of Plasmodium falciparum K13-Propeller Polymorphisms
Ménard D, Khim N, Beghain J, Adegnika A, Shafiul-Alam M, Amodu O, Rahim-Awab G, Barnadas C, Berry A, Boum Y, Bustos M, Cao J, Chen J, Collet L, Cui L, Thakur G, Dieye A, Djallé D, Dorkenoo M, Eboumbou-Moukoko C, Espino F, Fandeur T, Ferreira-da-Cruz M, Fola A, Fuehrer H, Hassan A, Herrera S, Hongvanthong B, Houzé S, Ibrahim M, Jahirul-Karim M, Jiang L, Kano S, Ali-Khan W, Khanthavong M, Kremsner P, Lacerda M, Leang R, Leelawong M, Li M, Lin K, Mazarati J, Ménard S, Morlais I, Muhindo-Mavoko H, Musset L, Na-Bangchang K, Nambozi M, Niaré K, Noedl H, Ouédraogo J, Pillai D, Pradines B, Quang-Phuc B, Ramharter M, Randrianarivelojosia M, Sattabongkot J, Sheikh-Omar A, Silué K, Sirima S, Sutherland C, Syafruddin D, Tahar R, Tang L, Touré O, Tshibangu-wa-Tshibangu P, Vigan-Womas I, Warsame M, Wini L, Zakeri S, Kim S, Eam R, Berne L, Khean C, Chy S, Ken M, Loch K, Canier L, Duru V, Legrand E, Barale J, Stokes B, Straimer J, Witkowski B, Fidock D, Rogier C, Ringwald P, Ariey F, Mercereau-Puijalon O. A Worldwide Map of Plasmodium falciparum K13-Propeller Polymorphisms. New England Journal Of Medicine 2016, 374: 2453-2464. PMID: 27332904, PMCID: PMC4955562, DOI: 10.1056/nejmoa1513137.Peer-Reviewed Original ResearchConceptsK13 mutationsRing-stage survival assayK13-propeller polymorphismsPlasmodium falciparum resistanceA578S mutationParasite clearanceRare nonsynonymous mutationsFalciparum resistanceAntimalarial resistanceArtemisinin resistanceNationwide surveillanceGlobal burdenSentinel sitesGeographic disparitiesSurvival assaysP. falciparum genesMalariaPropeller domainMajor determinantArtemisininMutationsNonsynonymous mutationsSuch resistancePolymorphismPatientsGenomic epidemiology of artemisinin resistant malaria
Amato R, Miotto O, Woodrow C, Almagro-Garcia J, Sinha I, Campino S, Mead D, Drury E, Kekre M, Sanders M, Amambua-Ngwa A, Amaratunga C, Amenga-Etego L, Andrianaranjaka V, Apinjoh T, Ashley E, Auburn S, Awandare G, Baraka V, Barry A, Boni M, Borrmann S, Bousema T, Branch O, Bull P, Chotivanich K, Conway D, Craig A, Day N, Djimdé A, Dolecek C, Dondorp A, Drakeley C, Duffy P, Echeverry D, Egwang T, Fairhurst R, Faiz A, Fanello C, Hien T, Hodgson A, Imwong M, Ishengoma D, Lim P, Lon C, Marfurt J, Marsh K, Mayxay M, Michon P, Mobegi V, Mokuolu O, Montgomery J, Mueller I, Kyaw M, Newton P, Nosten F, Noviyanti R, Nzila A, Ocholla H, Oduro A, Onyamboko M, Ouedraogo J, Phyo A, Plowe C, Price R, Pukrittayakamee S, Randrianarivelojosia M, Ringwald P, Ruiz L, Saunders D, Shayo A, Siba P, Takala-Harrison S, Thanh T, Thathy V, Verra F, Wendler J, White N, Ye H, Cornelius V, Giacomantonio R, Muddyman D, Henrichs C, Malangone C, Jyothi D, Pearson R, Rayner J, McVean G, Rockett K, Miles A, Vauterin P, Jeffery B, Manske M, Stalker J, MacInnis B, Kwiatkowski D. Genomic epidemiology of artemisinin resistant malaria. ELife 2016, 5: e08714. PMID: 26943619, PMCID: PMC4786412, DOI: 10.7554/elife.08714.Peer-Reviewed Original ResearchMeSH KeywordsAfricaAntimalarialsArtemisininsAsia, SoutheasternDrug ResistanceMalaria, FalciparumMolecular EpidemiologyPlasmodium falciparumConceptsKelch13 mutationsArtemisinin-resistant Plasmodium falciparumArtemisinin-resistant malariaResistant Plasmodium falciparumGenomic epidemiologyLarge global surveyPublic health surveillanceArtemisinin resistanceResistant malariaCurrent epidemicHealth surveillancePlasmodium falciparumAmino acid changesEpidemiologyKelch13Non-synonymous mutationsLessons learnt from 20 years surveillance of malaria drug resistance prior to the policy change in Burkina Faso.
Tinto H, Valea I, Ouédraogo J, Guiguemdé T. Lessons learnt from 20 years surveillance of malaria drug resistance prior to the policy change in Burkina Faso. Annals Of Parasitology 2016, 62: 17-24. PMID: 27262953, DOI: 10.17420/ap6201.27.Peer-Reviewed Original ResearchMeSH KeywordsAntimalarialsBurkina FasoDrug ResistanceHealth PolicyHumansMalaria, FalciparumPlasmodium falciparumConceptsDrug resistanceChloroquine resistanceYear surveillanceSeasonal malaria chemoprophylaxisIntermittent preventive treatmentMalaria drug resistanceSulfadoxine-pyrimethamine resistanceSystematic surveillance systemGood surveillance systemSurveillance systemLate recrudescenceMalaria chemoprophylaxisUncomplicated malariaSulfadoxine-pyrimethamineTreatment failurePregnant womenCombination therapyDevelopment of resistancePreventive treatmentReal prevalenceTreatment resistanceLow prevalenceSentinel sitesAntimalarial drugsBurkina Faso
2015
Prevalence of the dhfr and dhps Mutations among Pregnant Women in Rural Burkina Faso Five Years after the Introduction of Intermittent Preventive Treatment with Sulfadoxine-Pyrimethamine
Tahita M, Tinto H, Erhart A, Kazienga A, Fitzhenry R, VanOvermeir C, Rosanas-Urgell A, Ouedraogo J, Guiguemde R, Van geertruyden J, D’Alessandro U. Prevalence of the dhfr and dhps Mutations among Pregnant Women in Rural Burkina Faso Five Years after the Introduction of Intermittent Preventive Treatment with Sulfadoxine-Pyrimethamine. PLOS ONE 2015, 10: e0137440. PMID: 26368675, PMCID: PMC4569438, DOI: 10.1371/journal.pone.0137440.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntimalarialsBurkina FasoDihydropteroate SynthaseDrug CombinationsDrug ResistanceFemaleHumansMalaria, FalciparumMutationPlasmodium falciparumPregnancyPregnancy Trimester, SecondPregnancy Trimester, ThirdPrevalenceProtozoan ProteinsPyrimethamineSulfadoxineTetrahydrofolate DehydrogenaseYoung AdultConceptsIntermittent preventive treatmentPregnant womenPfdhps genesPreventive treatmentAntenatal careSulfadoxine-pyrimethamineThird trimesterDhps mutationsPfdhfr mutationsMalaria infectionMalaria symptomsHealth districtPfdhfr geneBlood samplesSP resistanceI164L mutationEndemic regionsReductase mutationMalaria controlDrug resistancePrevalenceAdverse effectsFive yearsWomenBurkina FasoEx vivo anti-malarial drug susceptibility of Plasmodium falciparum isolates from pregnant women in an area of highly seasonal transmission in Burkina Faso
Tahita M, Tinto H, Yarga S, Kazienga A, Traore/Coulibaly M, Valea I, Van Overmeir C, Rosanas-Urgell A, Ouedraogo J, Guiguemde R, van Geertruyden J, Erhart A, D’Alessandro U. Ex vivo anti-malarial drug susceptibility of Plasmodium falciparum isolates from pregnant women in an area of highly seasonal transmission in Burkina Faso. Malaria Journal 2015, 14: 251. PMID: 26088768, PMCID: PMC4474342, DOI: 10.1186/s12936-015-0769-1.Peer-Reviewed Original ResearchConceptsPregnant womenAnti-malarial drugsDrug sensitivity profilesParasite densityAnti-malarial drug susceptibilityDifferent drug sensitivity profilesUncomplicated Plasmodium falciparum malariaTreatment Efficacy TrialInfected pregnant womenArtemisinin-based combinationsPlasmodium falciparum malariaChloroquine-resistant isolatesHistidine-rich protein-2 assayPlasmodium falciparum isolatesGeometric mean IC50Low parasite densitiesP. falciparum parasitesTreatment of malariaFalciparum malariaRecurrent infectionsMean IC50Efficacy trialsFalciparum isolatesMethodsThe studyResistant parasitesRandomized Noninferiority Trial of Dihydroartemisinin-Piperaquine Compared with Sulfadoxine-Pyrimethamine plus Amodiaquine for Seasonal Malaria Chemoprevention in Burkina Faso
Zongo I, Milligan P, Compaore Y, Some A, Greenwood B, Tarning J, Rosenthal P, Sutherland C, Nosten F, Ouedraogo J. Randomized Noninferiority Trial of Dihydroartemisinin-Piperaquine Compared with Sulfadoxine-Pyrimethamine plus Amodiaquine for Seasonal Malaria Chemoprevention in Burkina Faso. Antimicrobial Agents And Chemotherapy 2015, 59: 4387-4396. PMID: 25918149, PMCID: PMC4505196, DOI: 10.1128/aac.04923-14.Peer-Reviewed Original ResearchConceptsSeasonal malaria chemopreventionMalaria chemopreventionAlternative drugsControl groupPrimary outcome measureSeasonal malaria transmissionRandomized noninferiority trialPotential alternative drugDihydroartemisinin-PiperaquinePfdhps mutationsClinical malariaMalaria attacksSulfadoxine-pyrimethamineOdds ratioNoninferiority trialOutcome measuresDHAPQChildren 3Malaria transmissionDrug resistanceAntifolate resistanceChemopreventionChildrenAmodiaquineTrialsDynamic of plasmodium falciparum chloroquine resistance transporter gene Pfcrt K76T mutation five years after withdrawal of chloroquine in Burkina Faso
Sondo P, Derra K, Tarnagda Z, Nakanabo S, Zampa O, Kazienga A, Valea I, Sorgho H, Ouedraogo J, Guiguemde T, Tinto H. Dynamic of plasmodium falciparum chloroquine resistance transporter gene Pfcrt K76T mutation five years after withdrawal of chloroquine in Burkina Faso. Pan African Medical Journal 2015, 21: 101. PMID: 26516402, PMCID: PMC4606025, DOI: 10.11604/pamj.2015.21.101.6437.Peer-Reviewed Original Research
2014
Polymorphisms in Plasmodium falciparum Chloroquine Resistance Transporter and Multidrug Resistance 1 Genes: Parasite Risk Factors That Affect Treatment Outcomes for P. falciparum Malaria After Artemether-Lumefantrine and Artesunate-Amodiaquine
Venkatesan M, Gadalla N, Stepniewska K, Dahal P, Nsanzabana C, Moriera C, Price R, Mårtensson A, Rosenthal P, Dorsey G, Sutherland C, Guérin P, Davis T, Ménard D, Adam I, Ademowo G, Arze C, Baliraine F, Berens-Riha N, Björkman A, Borrmann S, Checchi F, Desai M, Dhorda M, Djimdé A, El-Sayed B, Eshetu T, Eyase F, Falade C, Faucher J, Fröberg G, Grivoyannis A, Hamour S, Houzé S, Johnson J, Kamugisha E, Kariuki S, Kiechel J, Kironde F, Kofoed P, LeBras J, Malmberg M, Mwai L, Ngasala B, Nosten F, Nsobya S, Nzila A, Oguike M, Otienoburu S, Ogutu B, Ouédraogo J, Piola P, Rombo L, Schramm B, Somé A, Thwing J, Ursing J, Wong R, Zeynudin A, Zongo I, Plowe C, Sibley C, Asaq Molecular Marker Study Group. Polymorphisms in Plasmodium falciparum Chloroquine Resistance Transporter and Multidrug Resistance 1 Genes: Parasite Risk Factors That Affect Treatment Outcomes for P. falciparum Malaria After Artemether-Lumefantrine and Artesunate-Amodiaquine. American Journal Of Tropical Medicine And Hygiene 2014, 91: 833-843. PMID: 25048375, PMCID: PMC4183414, DOI: 10.4269/ajtmh.14-0031.Peer-Reviewed Original ResearchMeSH KeywordsAmino Acid SubstitutionAmodiaquineAntimalarialsArtemetherArtemisininsChildChild, PreschoolChloroquineDatasets as TopicDrug CombinationsDrug ResistanceDrug Therapy, CombinationEthanolaminesFluorenesGenetic MarkersGenotypeHumansInfantKaplan-Meier EstimateLumefantrineMalaria, FalciparumMembrane Transport ProteinsMultidrug Resistance-Associated ProteinsPlasmodium falciparumPolymorphism, GeneticProtozoan ProteinsRisk FactorsConceptsArtemether-lumefantrineP. falciparum multidrug resistance 1 genePlasmodium falciparum chloroquine resistance transporterPfmdr1 copy numberArtemisinin combination therapyIndividual patient dataChloroquine resistance transporterMultidrug resistance 1 geneWorldWide Antimalarial Resistance NetworkParasitologic cureCombination therapyParasite polymorphismsPartner drugsTherapeutic responseClinical trialsRelevant outcomesArtemisinin componentPatient dataResistance transporterStandardized methodPolymorphismPatientsPfmdr1PfcrtAmodiaquineSelection of Drug Resistance-Mediating Plasmodium falciparum Genetic Polymorphisms by Seasonal Malaria Chemoprevention in Burkina Faso
Somé A, Zongo I, Compaoré Y, Sakandé S, Nosten F, Ouédraogo J, Rosenthal P. Selection of Drug Resistance-Mediating Plasmodium falciparum Genetic Polymorphisms by Seasonal Malaria Chemoprevention in Burkina Faso. Antimicrobial Agents And Chemotherapy 2014, 58: 3660-3665. PMID: 24733476, PMCID: PMC4068591, DOI: 10.1128/aac.02406-14.Peer-Reviewed Original ResearchConceptsSeasonal malaria chemopreventionAQ/SPMalaria chemopreventionSingle nucleotide polymorphismsP. falciparum crtPfcrt 76TResistance-mediating polymorphismsMalaria control measuresPCR-positive samplesMonthly DPPfdhfr 108NPfdhfr 51IPfmdr1 86YSulfadoxine-pyrimethamineTreatment armsDevelopment of resistanceTransmission seasonControl groupP. falciparumSNP prevalenceGenetic polymorphismsRegular useAntifolate antimalarialsMonthsBurkina Faso
2013
Multiple populations of artemisinin-resistant Plasmodium falciparum in Cambodia
Miotto O, Almagro-Garcia J, Manske M, MacInnis B, Campino S, Rockett K, Amaratunga C, Lim P, Suon S, Sreng S, Anderson J, Duong S, Nguon C, Chuor C, Saunders D, Se Y, Lon C, Fukuda M, Amenga-Etego L, Hodgson A, Asoala V, Imwong M, Takala-Harrison S, Nosten F, Su X, Ringwald P, Ariey F, Dolecek C, Hien T, Boni M, Thai C, Amambua-Ngwa A, Conway D, Djimdé A, Doumbo O, Zongo I, Ouedraogo J, Alcock D, Drury E, Auburn S, Koch O, Sanders M, Hubbart C, Maslen G, Ruano-Rubio V, Jyothi D, Miles A, O'Brien J, Gamble C, Oyola S, Rayner J, Newbold C, Berriman M, Spencer C, McVean G, Day N, White N, Bethell D, Dondorp A, Plowe C, Fairhurst R, Kwiatkowski D. Multiple populations of artemisinin-resistant Plasmodium falciparum in Cambodia. Nature Genetics 2013, 45: 648-655. PMID: 23624527, PMCID: PMC3807790, DOI: 10.1038/ng.2624.Peer-Reviewed Original Research
2011
Host candidate gene polymorphisms and clearance of drug-resistant Plasmodium falciparum parasites
Diakite M, Achidi E, Achonduh O, Craik R, Djimde A, Evehe M, Green A, Hubbart C, Ibrahim M, Jeffreys A, Khan B, Kimani F, Kwiatkowski D, Mbacham W, Jezan S, Ouedraogo J, Rockett K, Rowlands K, Tagelsir N, Tekete M, Zongo I, Ranford-Cartwright L. Host candidate gene polymorphisms and clearance of drug-resistant Plasmodium falciparum parasites. Malaria Journal 2011, 10: 250. PMID: 21867552, PMCID: PMC3177816, DOI: 10.1186/1475-2875-10-250.Peer-Reviewed Original ResearchConceptsDrug-resistant parasitesHuman genomeAnti-malarial drugsSignificant associationDrug treatmentResistant parasitesAnti-inflammatory cytokine responseTh1/Th2 balanceDrug-resistant Plasmodium falciparum parasitesDrug-resistant P. falciparumMolecular testsPlasmodium falciparum infectionPlasmodium falciparum parasitesDrug resistance profilesDrug-resistant infectionsImmune response lociCandidate gene polymorphismsAbility of parasitesTh2 balanceFalciparum infectionCytokine responsesMalaria infectionOdds ratioClearance phenotypeEnhanced clearance
2008
Chloroquine‐resistance molecular markers (Pfcrt T76 and Pfmdr‐1 Y86) and amodiaquine resistance in Burkina Faso
Tinto H, Guekoun L, Zongo I, Guiguemdé R, D’Alessandro U, Ouédraogo J. Chloroquine‐resistance molecular markers (Pfcrt T76 and Pfmdr‐1 Y86) and amodiaquine resistance in Burkina Faso. Tropical Medicine And International Health 2008, 13: 238-240. PMID: 18304270, DOI: 10.1111/j.1365-3156.2007.01995.x.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAmodiaquineAnimalsAntimalarialsBurkina FasoChildChild, PreschoolChloroquineDrug ResistanceHumansInfantInfant, NewbornMalaria, FalciparumMembrane Transport ProteinsMultidrug Resistance-Associated ProteinsMutationPlasmodium falciparumPolymerase Chain ReactionPrevalenceProtozoan ProteinsTreatment FailureTreatment Outcome
2007
Sulfadoxine-pyrimethamine efficacy and selection of Plasmodium falciparum DHFR mutations in Burkina Faso before its introduction as intermittent preventive treatment for pregnant women.
Tinto H, Ouédraogo J, Zongo I, van Overmeir C, van Marck E, Guiguemdé T, D'Alessandro U. Sulfadoxine-pyrimethamine efficacy and selection of Plasmodium falciparum DHFR mutations in Burkina Faso before its introduction as intermittent preventive treatment for pregnant women. American Journal Of Tropical Medicine And Hygiene 2007, 76: 608-13. PMID: 17426157, DOI: 10.4269/ajtmh.2007.76.608.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAnimalsAntimalarialsBurkina FasoChildChild, PreschoolChloroquineDrug Administration ScheduleDrug CombinationsDrug ResistanceFemaleGenotypeHumansInfantMalaria, FalciparumMaleMutationPlasmodium falciparumPregnancyPregnancy Complications, ParasiticPyrimethamineSelection, GeneticSulfadoxineTetrahydrofolate DehydrogenaseConceptsSulfadoxine-pyrimethamine efficacyTriple dhfr mutationDHFR mutationsRecurrent parasitemiaIntermittent preventive treatmentSulfadoxine-pyrimethamine resistanceYears of ageSuch high prevalenceDihydropteroate synthetase (Pfdhps) mutationsPCR-restriction fragment length polymorphismSulfadoxine-pyrimethamineTreatment failurePregnant womenPolymerase chain reactionPreventive treatmentHigh prevalenceNew infectionsChain reactionMutant parasitesPatientsParasitemiaTreatmentFragment length polymorphismPrevalenceEfficacy
2006
Roles of specific Plasmodium falciparum mutations in resistance to amodiaquine and sulfadoxine-pyrimethamine in Burkina Faso.
Dokomajilar C, Lankoande Z, Dorsey G, Zongo I, Ouedraogo J, ROSENTHAL P. Roles of specific Plasmodium falciparum mutations in resistance to amodiaquine and sulfadoxine-pyrimethamine in Burkina Faso. American Journal Of Tropical Medicine And Hygiene 2006, 75: 162-5. PMID: 16837725, DOI: 10.4269/ajtmh.2006.75.162.Peer-Reviewed Original ResearchMeSH KeywordsAmodiaquineAnimalsAntimalarialsBurkina FasoDihydropteroate SynthaseDrug CombinationsDrug ResistanceGenes, MDRHumansMembrane ProteinsMembrane Transport ProteinsMutationPlasmodium falciparumPolymorphism, GeneticProtozoan ProteinsPyrimethamineRecurrenceSulfadoxineTetrahydrofolate DehydrogenaseConceptsUncomplicated Plasmodium falciparum malariaPlasmodium falciparum mutationsPlasmodium falciparum malariaP. falciparum resistanceFalciparum malariaFalciparum resistanceNew infectionsAmodiaquineDhfr-164LBobo-DioulassoSignificant increaseBurkina FasoSame mutationTreatmentKey polymorphismsMutationsTarget genesTherapyInfectionMalariaPrevalenceRecrudescence